CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TRMT2B (ImmuneEditome ID:79979)

1. Gene summary of enriched editing regions for TRMT2B

check button Gene summary
Gene informationGene symbol

TRMT2B

Gene ID

79979

GeneSynonymsCXorf34|dJ341D10.3
GeneCytomap

Xq22.1

GeneTypeprotein-coding
GeneDescriptiontRNA (uracil-5-)-methyltransferase homolog B|TRM2 homolog|TRM2 homolog B|TRM2 tRNA methyltransferase 2 homolog B|rRNA (uracil-5-)-methyltransferase TRMT2B|tRNA (uracil(54)-C(5))-methyltransferase homolog|tRNA (uracil-5-)-methyltransferase homolog
GeneModificationdate20230517
UniprotIDQ96GJ1
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chrX:101009521-101010435:-ENST00000372935.4ENSG00000188917.13TRMT2BUTR3AluSz,AluSx1chrX:101009521-101010435:-.alignment
chrX:101009521-101010435:-ENST00000372936.3ENSG00000188917.13TRMT2BUTR3AluSz,AluSx1chrX:101009521-101010435:-.alignment
chrX:101009521-101010435:-ENST00000372939.4ENSG00000188917.13TRMT2BUTR3AluSz,AluSx1chrX:101009521-101010435:-.alignment
chrX:101009521-101010435:-ENST00000545398.4ENSG00000188917.13TRMT2BUTR3AluSz,AluSx1chrX:101009521-101010435:-.alignment
chrX:101025828-101028361:-ENST00000478422.1ENSG00000188917.13TRMT2BncRNA_intronicL1MA10,AluSx1,AluSx,GA-rich,AluSc,L2a,AluSq2chrX:101025828-101028361:-.alignment
chrX:101030087-101031219:-ENST00000478422.1ENSG00000188917.13TRMT2BncRNA_intronicHAL1,AluSz,AluSg,AluJochrX:101030087-101031219:-.alignment
chrX:101047670-101048616:-ENST00000478422.1ENSG00000188917.13TRMT2BncRNA_intronic(AC)n,AluJo,AluSx1chrX:101047670-101048616:-.alignment


Top

2. Tumor-specific enriched editing regions for TRMT2B


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chrX:101009521-101010435:-BRCAEER1.5518e-14image
ENSG00000188917.13,TRMT2BBRCAEAG1.8297e-14image
chrX:101009521-101010435:-HNSCEER2.6579e-02image
ENSG00000188917.13,TRMT2BHNSCEAG2.6418e-02image
chrX:101009521-101010435:-KIRCEER3.3196e-06image
ENSG00000188917.13,TRMT2BKIRCEAG2.9030e-06image
chrX:101009521-101010435:-KIRPEER3.5505e-04image
ENSG00000188917.13,TRMT2BKIRPEAG3.8220e-04image
chrX:101009521-101010435:-THCAEER6.8058e-09image
ENSG00000188917.13,TRMT2BTHCAEAG6.3121e-09image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chrX:101009521-101010435:-LUADPathEER1.7881e-029.7305e-030.1153image
ENSG00000188917.13,TRMT2BLUADPathEAG2.3363e-021.3053e-020.1106image
chrX:101009521-101010435:-MESOPathEER4.5168e-047.8664e-03-0.2881image
ENSG00000188917.13,TRMT2BMESOPathEAG4.5168e-047.8664e-03-0.2881image
chrX:101009521-101010435:-THCAPathEER5.0550e-041.6248e-030.1403image
ENSG00000188917.13,TRMT2BTHCAPathEAG4.9150e-041.6153e-030.1404image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TRMT2B


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chrX:101009521-101010435:-BRCAEERENSG00000160710,ADAR0.38821.4877e-356.6791e-490.4284imageNNADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-STADEERENSG00000187608,ISG150.33126.9889e-082.1341e-160.4111imageNNISG15Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000123595,RAB9A-0.57852.3602e-021.1894e-05-0.5140imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000102393,GLA-0.53034.1804e-026.7877e-04-0.4107imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000187605,TET3-0.39083.3447e-047.8604e-09-0.4224imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000168071,CCDC88B0.28641.6714e-021.1580e-080.4180imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-DLBCEERENSG00000166741,NNMT0.62031.4276e-026.1257e-050.5453imageNNNAMacrophages_M2GSVA_HALLMARK_COAGULATION
chrX:101009521-101010435:-DLBCEERENSG00000167779,IGFBP60.57781.5562e-022.1857e-080.7052imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000105711,SCN1B0.60941.6634e-021.1189e-060.6372imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000185127,C6orf120-0.59401.6679e-027.6945e-04-0.4691imageNNNAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chrX:101009521-101010435:-BRCAEERENSG00000160710,ADAR0.38821.4877e-356.6791e-490.4284imageNNADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-STADEERENSG00000187608,ISG150.33126.9889e-082.1341e-160.4111imageNNISG15Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000123595,RAB9A-0.57852.3602e-021.1894e-05-0.5140imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000102393,GLA-0.53034.1804e-026.7877e-04-0.4107imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000187605,TET3-0.39083.3447e-047.8604e-09-0.4224imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000168071,CCDC88B0.28641.6714e-021.1580e-080.4180imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-DLBCEERENSG00000166741,NNMT0.62031.4276e-026.1257e-050.5453imageNNNAMacrophages_M2GSVA_HALLMARK_COAGULATION
chrX:101009521-101010435:-DLBCEERENSG00000167779,IGFBP60.57781.5562e-022.1857e-080.7052imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000105711,SCN1B0.60941.6634e-021.1189e-060.6372imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000185127,C6orf120-0.59401.6679e-027.6945e-04-0.4691imageNNNAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chrX:101009521-101010435:-BRCAEERENSG00000160710,ADAR0.38821.4877e-356.6791e-490.4284imageNNADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-STADEERENSG00000187608,ISG150.33126.9889e-082.1341e-160.4111imageNNISG15Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000123595,RAB9A-0.57852.3602e-021.1894e-05-0.5140imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000102393,GLA-0.53034.1804e-026.7877e-04-0.4107imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000187605,TET3-0.39083.3447e-047.8604e-09-0.4224imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000168071,CCDC88B0.28641.6714e-021.1580e-080.4180imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-DLBCEERENSG00000166741,NNMT0.62031.4276e-026.1257e-050.5453imageNNNAMacrophages_M2GSVA_HALLMARK_COAGULATION
chrX:101009521-101010435:-DLBCEERENSG00000167779,IGFBP60.57781.5562e-022.1857e-080.7052imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000105711,SCN1B0.60941.6634e-021.1189e-060.6372imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000185127,C6orf120-0.59401.6679e-027.6945e-04-0.4691imageNNNAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
chrX:101009521-101010435:-BRCAEERENSG00000160710,ADAR0.38821.4877e-356.6791e-490.4284imageNNADARMacrophages_M1GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-STADEERENSG00000187608,ISG150.33126.9889e-082.1341e-160.4111imageNNISG15Dendritic_cells_activatedGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000123595,RAB9A-0.57852.3602e-021.1894e-05-0.5140imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_ANDROGEN_RESPONSE
chrX:101009521-101010435:-KICHEERENSG00000102393,GLA-0.53034.1804e-026.7877e-04-0.4107imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000187605,TET3-0.39083.3447e-047.8604e-09-0.4224imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chrX:101009521-101010435:-UCECEERENSG00000168071,CCDC88B0.28641.6714e-021.1580e-080.4180imageNNNAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
chrX:101009521-101010435:-DLBCEERENSG00000166741,NNMT0.62031.4276e-026.1257e-050.5453imageNNNAMacrophages_M2GSVA_HALLMARK_COAGULATION
chrX:101009521-101010435:-DLBCEERENSG00000167779,IGFBP60.57781.5562e-022.1857e-080.7052imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000105711,SCN1B0.60941.6634e-021.1189e-060.6372imageNNNAMacrophages_M2GSVA_HALLMARK_MYOGENESIS
chrX:101009521-101010435:-DLBCEERENSG00000185127,C6orf120-0.59401.6679e-027.6945e-04-0.4691imageNNNAB_cells_memoryGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING

More results



Top

4. Enriched editing regions and immune related splicing for TRMT2B


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000188917.13,TRMT2B
COADEAGMEXENSG00000176261.11chr132627507:32627544:32633644:32634110:32634701:32634792:32650432:326509030.22693.4906e-027.1839e-120.4006imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000188917.13,TRMT2B
COADEAGIRENSG00000090060.13chr1496532330:96532649:96534490:965345630.25101.1799e-027.0765e-150.4494imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM5;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALING
ENSG00000188917.13,TRMT2B
COADEAGMEXENSG00000176261.11chr132627507:32627544:32633644:32634110:32634732:32634792:32650432:326509030.22873.2138e-027.7793e-120.4000imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;ZNF184NAEosinophilsGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000188917.13,TRMT2B
COADEAGIRENSG00000135392.11chr1255820959:55823189:55823401:558235080.23033.2204e-024.2005e-230.5530imageNACIN1;ADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDF1;ZNF184NAMast_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000188917.13,TRMT2B
COADEAGIRENSG00000134255.9chr1111174878:111182318:111182798:1111829570.23962.0013e-023.8211e-210.5330imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000188917.13,TRMT2B
TGCTEAGESENSG00000169727.8chr1782051928:82051964:82052374:82052459:82053273:820533660.45761.3693e-053.2487e-070.4078imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
ENSG00000188917.13,TRMT2B
TGCTEAGA5ENSG00000169727.8chr1782053273:82053366:82051874:82051964:82051874:82052459-0.46509.6941e-062.0164e-07-0.4142imageNACIN1;AIFM1;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NAMacrophages_M2GSVA_HALLMARK_ESTROGEN_RESPONSE_EARLY
ENSG00000188917.13,TRMT2B
TGCTEAGA5ENSG00000167962.8chr162001003:2001191:2001591:2001700:2001582:20017000.41632.2200e-041.7800e-070.4159imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDF1;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_HEDGEHOG_SIGNALING
chrX:101009521-101010435:-
TGCTEERESENSG00000105865.6chr7107571144:107571266:107573703:107573821:107575187:1075752820.32551.5162e-034.5425e-060.4128imageNNNAB_cells_naiveGSVA_HALLMARK_MYOGENESIS
ENSG00000188917.13,TRMT2B
TGCTEAGESENSG00000117569.14chr196804799:96804939:96806418:96806452:96806865:96806958-0.30491.6537e-034.5642e-06-0.4078imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FTO;FUS;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHSRP;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RBM5;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;YTHDF1NAMacrophages_M2GSVA_HALLMARK_GLYCOLYSIS

More results



Top

5. Enriched editing regions and immune infiltration for TRMT2B


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chrX:101009521-101010435:-BLCAEERT_cells_CD4_memory_activated1.3706e-060.2387image
ENSG00000188917.13,TRMT2BBLCAEAGT_cells_CD4_memory_activated1.5491e-060.2375image
chrX:101009521-101010435:-BRCAEERDendritic_cells_activated1.7804e-050.1309image
ENSG00000188917.13,TRMT2BBRCAEAGDendritic_cells_activated1.9851e-050.1299image
chrX:101009521-101010435:-CESCEERT_cells_CD85.8255e-040.1965image
ENSG00000188917.13,TRMT2BCESCEAGT_cells_CD85.7054e-040.1968image
chrX:101009521-101010435:-CHOLEERNK_cells_activated1.1698e-020.4214image
ENSG00000188917.13,TRMT2BCHOLEAGNK_cells_activated1.1271e-020.4234image
chrX:101009521-101010435:-COADEERMacrophages_M03.5254e-02-0.1294image
ENSG00000188917.13,TRMT2BCOADEAGDendritic_cells_activated5.0821e-040.2098image
chrX:101009521-101010435:-DLBCEERMacrophages_M22.9594e-020.3143image
ENSG00000188917.13,TRMT2BDLBCEAGMacrophages_M22.9727e-020.3140image
chrX:101009521-101010435:-ESCAEERT_cells_CD81.1231e-020.1994image
chrX:101030087-101031219:-ESCAEERB_cells_memory1.1784e-02-0.5511image
ENSG00000188917.13,TRMT2BESCAEAGT_cells_CD81.6911e-020.1880image
chrX:101009521-101010435:-GBMEERMacrophages_M02.0996e-03-0.2392image
ENSG00000188917.13,TRMT2BGBMEAGMacrophages_M02.2344e-03-0.2378image
chrX:101009521-101010435:-HNSCEERT_cells_regulatory_(Tregs)1.1884e-03-0.1486image
ENSG00000188917.13,TRMT2BHNSCEAGT_cells_regulatory_(Tregs)1.1282e-03-0.1493image
chrX:101009521-101010435:-KICHEERT_cells_CD4_memory_activated3.2223e-060.5413image
ENSG00000188917.13,TRMT2BKICHEAGT_cells_CD4_memory_activated3.1991e-060.5415image
chrX:101009521-101010435:-KIRCEERPlasma_cells7.0368e-060.2276image
ENSG00000188917.13,TRMT2BKIRCEAGPlasma_cells7.6570e-060.2264image
chrX:101009521-101010435:-KIRPEERMacrophages_M13.7451e-020.1236image
ENSG00000188917.13,TRMT2BKIRPEAGMacrophages_M13.9004e-020.1226image
ENSG00000188917.13,TRMT2BLAMLEAGT_cells_CD4_naive4.7972e-030.2330image
chrX:101009521-101010435:-LGGEERMacrophages_M03.2539e-02-0.0961image
ENSG00000188917.13,TRMT2BLGGEAGMacrophages_M03.2785e-02-0.0960image
chrX:101009521-101010435:-LIHCEERMacrophages_M11.9757e-030.1682image
ENSG00000188917.13,TRMT2BLIHCEAGMacrophages_M11.9914e-030.1681image
chrX:101009521-101010435:-LUADEERT_cells_CD81.5465e-050.1918image
ENSG00000188917.13,TRMT2BLUADEAGT_cells_CD83.0546e-050.1849image
chrX:101009521-101010435:-LUSCEERT_cells_CD4_memory_activated1.1966e-050.1964image
ENSG00000188917.13,TRMT2BLUSCEAGT_cells_CD4_memory_activated1.3214e-050.1954image
chrX:101009521-101010435:-MESOEERMacrophages_M13.4406e-020.2368image
ENSG00000188917.13,TRMT2BMESOEAGMacrophages_M13.4406e-020.2368image
chrX:101009521-101010435:-OVEERT_cells_follicular_helper1.4364e-040.2222image
ENSG00000188917.13,TRMT2BOVEAGMacrophages_M12.6504e-040.2130image
chrX:101009521-101010435:-PAADEERT_cells_gamma_delta3.2430e-040.2687image
ENSG00000188917.13,TRMT2BPAADEAGT_cells_gamma_delta3.0615e-040.2698image
chrX:101009521-101010435:-PCPGEERT_cells_regulatory_(Tregs)2.7950e-020.1634image
ENSG00000188917.13,TRMT2BPCPGEAGT_cells_regulatory_(Tregs)2.9662e-020.1617image
chrX:101009521-101010435:-PRADEERT_cells_CD87.1708e-040.1514image
ENSG00000188917.13,TRMT2BPRADEAGT_cells_CD86.7054e-040.1522image
chrX:101009521-101010435:-READEERT_cells_CD4_memory_activated3.7981e-03-0.2943image
ENSG00000188917.13,TRMT2BREADEAGT_cells_CD4_memory_activated3.7981e-03-0.2943image
chrX:101009521-101010435:-SARCEERT_cells_CD4_memory_resting3.1195e-03-0.1916image
ENSG00000188917.13,TRMT2BSARCEAGT_cells_CD4_memory_resting3.0978e-03-0.1918image
chrX:101009521-101010435:-SKCMEERNK_cells_activated8.1041e-030.1237image
ENSG00000188917.13,TRMT2BSKCMEAGNK_cells_activated7.6707e-030.1246image
chrX:101009521-101010435:-STADEERDendritic_cells_activated2.6937e-050.2172image
chrX:101025828-101028361:-STADEERDendritic_cells_resting1.6389e-02-0.4948image
ENSG00000188917.13,TRMT2BSTADEAGDendritic_cells_activated2.7207e-050.2171image
chrX:101009521-101010435:-TGCTEERMacrophages_M22.2159e-02-0.1886image
ENSG00000188917.13,TRMT2BTGCTEAGMacrophages_M22.1715e-02-0.1892image
chrX:101009521-101010435:-THCAEERT_cells_regulatory_(Tregs)9.5759e-060.1959image
ENSG00000188917.13,TRMT2BTHCAEAGT_cells_regulatory_(Tregs)9.6462e-060.1959image
chrX:101009521-101010435:-THYMEERMacrophages_M24.4944e-040.3206image
ENSG00000188917.13,TRMT2BTHYMEAGMacrophages_M24.6025e-040.3201image
chrX:101009521-101010435:-UCECEERT_cells_regulatory_(Tregs)2.7912e-020.1677image
chrX:101009521-101010435:-UCSEERMacrophages_M01.2667e-020.3403image
ENSG00000188917.13,TRMT2BUCSEAGMacrophages_M01.3485e-020.3374image
chrX:101009521-101010435:-UVMEERT_cells_follicular_helper4.3872e-02-0.2350image
ENSG00000188917.13,TRMT2BUVMEAGT_cells_follicular_helper4.3334e-02-0.2356image


Top

6. Enriched editing regions and immune gene sets for TRMT2B


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chrX:101009521-101010435:-THCAEER3.9017e-02image3.0288e-020.0966image
ENSG00000188917.13,TRMT2BTHCAEAG3.8861e-02image3.0774e-020.0963image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chrX:101009521-101010435:-LGGEER1.4454e-04-0.17001.7933e-04-0.16769.7739e-05-0.17424.0432e-02-0.0921image
ENSG00000188917.13,TRMT2BLGGEAG1.4088e-04-0.17031.6893e-04-0.16839.6479e-05-0.17443.9026e-02-0.0928image
chrX:101009521-101010435:-LIHCEER3.4772e-03-0.15904.3201e-04-0.19105.3300e-04-0.18809.2762e-030.1417image
ENSG00000188917.13,TRMT2BLIHCEAG3.4738e-03-0.15904.3425e-04-0.19095.3626e-04-0.18799.3294e-030.1416image
chrX:101009521-101010435:-LUADEER3.0579e-080.24436.9190e-080.23814.1207e-070.22391.9956e-040.1654image
ENSG00000188917.13,TRMT2BLUADEAG1.0617e-070.23451.1811e-070.23371.0132e-060.21625.8894e-040.1529image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000188917.13,TRMT2BACCGSVA_HALLMARK_P53_PATHWAYEAG1.7361e-02-0.2705image
chrX:101009521-101010435:-ACCGSVA_HALLMARK_P53_PATHWAYEER1.7361e-02-0.2705image
ENSG00000188917.13,TRMT2BBLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG1.3060e-080.2795image
chrX:101009521-101010435:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER7.0910e-090.2843image
ENSG00000188917.13,TRMT2BBRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG9.8984e-230.2934image
chrX:101009521-101010435:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER8.5025e-240.3010image
ENSG00000188917.13,TRMT2BCESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.3854e-060.2633image
chrX:101009521-101010435:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.3807e-060.2633image
chrX:101009521-101010435:-CHOLGSVA_HALLMARK_IL2_STAT5_SIGNALINGEER1.9054e-03-0.5065image
ENSG00000188917.13,TRMT2BCHOLGSVA_HALLMARK_UV_RESPONSE_UPEAG1.9180e-03-0.5062image
ENSG00000188917.13,TRMT2BCOADGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEAG1.4547e-03-0.1925image
chrX:101009521-101010435:-COADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.7090e-02-0.1221image
ENSG00000188917.13,TRMT2BDLBCGSVA_HALLMARK_MYOGENESISEAG1.1957e-020.3600image
chrX:101009521-101010435:-DLBCGSVA_HALLMARK_MYOGENESISEER1.1898e-020.3602image
chrX:101009521-101010435:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6988e-040.2921image
ENSG00000188917.13,TRMT2BESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7863e-040.2912image
chrX:101009521-101010435:-GBMGSVA_HALLMARK_MYC_TARGETS_V2EER1.6860e-03-0.2441image
ENSG00000188917.13,TRMT2BGBMGSVA_HALLMARK_MYC_TARGETS_V2EAG1.7188e-03-0.2437image
ENSG00000188917.13,TRMT2BHNSCGSVA_HALLMARK_SPERMATOGENESISEAG2.5958e-09-0.2695image
chrX:101009521-101010435:-HNSCGSVA_HALLMARK_SPERMATOGENESISEER2.3561e-09-0.2702image
chrX:101009521-101010435:-KICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER1.2054e-03-0.3929image
ENSG00000188917.13,TRMT2BKICHGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.2070e-03-0.3929image
ENSG00000188917.13,TRMT2BKIRCGSVA_HALLMARK_APICAL_SURFACEEAG2.7805e-02-0.1124image
chrX:101009521-101010435:-KIRCGSVA_HALLMARK_APICAL_SURFACEEER2.0506e-02-0.1185image
chrX:101009521-101010435:-KIRPGSVA_HALLMARK_PROTEIN_SECRETIONEER7.3563e-06-0.2625image
ENSG00000188917.13,TRMT2BKIRPGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.8745e-06-0.2633image
chrX:101009521-101010435:-LAMLGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9494e-02-0.1994image
ENSG00000188917.13,TRMT2BLAMLGSVA_HALLMARK_DNA_REPAIREAG1.4653e-03-0.2619image
chrX:101009521-101010435:-LGGGSVA_HALLMARK_PEROXISOMEEER2.4208e-04-0.1643image
ENSG00000188917.13,TRMT2BLGGGSVA_HALLMARK_PEROXISOMEEAG2.2935e-04-0.1649image
ENSG00000188917.13,TRMT2BLIHCGSVA_HALLMARK_COAGULATIONEAG2.4335e-060.2539image
chrX:101009521-101010435:-LIHCGSVA_HALLMARK_COAGULATIONEER2.3696e-060.2542image
chrX:101009521-101010435:-LUADGSVA_HALLMARK_E2F_TARGETSEER3.0033e-100.2766image
ENSG00000188917.13,TRMT2BLUADGSVA_HALLMARK_E2F_TARGETSEAG9.8714e-100.2684image
chrX:101009521-101010435:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.1318e-040.1665image
ENSG00000188917.13,TRMT2BLUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1653e-040.1664image
chrX:101009521-101010435:-MESOGSVA_HALLMARK_MYC_TARGETS_V1EER1.8536e-020.2628image
ENSG00000188917.13,TRMT2BMESOGSVA_HALLMARK_MYC_TARGETS_V1EAG1.8536e-020.2628image
ENSG00000188917.13,TRMT2BOVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.0436e-100.3571image
chrX:101009521-101010435:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.7266e-100.3534image
ENSG00000188917.13,TRMT2BPAADGSVA_HALLMARK_BILE_ACID_METABOLISMEAG2.5718e-02-0.1686image
chrX:101009521-101010435:-PAADGSVA_HALLMARK_BILE_ACID_METABOLISMEER2.5491e-02-0.1689image
ENSG00000188917.13,TRMT2BPCPGGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.1178e-02-0.1882image
chrX:101009521-101010435:-PCPGGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.1822e-02-0.1868image
chrX:101009521-101010435:-PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER1.3979e-06-0.2147image
ENSG00000188917.13,TRMT2BPRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.0865e-06-0.2168image
ENSG00000188917.13,TRMT2BREADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG9.8782e-04-0.3327image
chrX:101009521-101010435:-READGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER9.8782e-04-0.3327image
ENSG00000188917.13,TRMT2BSARCGSVA_HALLMARK_P53_PATHWAYEAG6.7455e-040.2198image
chrX:101009521-101010435:-SARCGSVA_HALLMARK_P53_PATHWAYEER6.7426e-040.2198image
ENSG00000188917.13,TRMT2BSKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEAG3.5714e-04-0.1663image
chrX:101009521-101010435:-SKCMGSVA_HALLMARK_ANDROGEN_RESPONSEEER4.1210e-04-0.1645image
ENSG00000188917.13,TRMT2BSTADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.7634e-040.1815image
chrX:101009521-101010435:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER5.2353e-050.2095image
chrX:101030087-101031219:-STADGSVA_HALLMARK_MYOGENESISEER1.9488e-020.4551image
chrX:101025828-101028361:-STADGSVA_HALLMARK_KRAS_SIGNALING_DNEER4.2891e-020.4256image
chrX:101009521-101010435:-TGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER2.1493e-03-0.2512image
ENSG00000188917.13,TRMT2BTGCTGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG2.1118e-03-0.2516image
chrX:101009521-101010435:-THCAGSVA_HALLMARK_HEME_METABOLISMEER1.0714e-05-0.1949image
ENSG00000188917.13,TRMT2BTHCAGSVA_HALLMARK_HEME_METABOLISMEAG1.1309e-05-0.1944image
chrX:101009521-101010435:-THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER6.5175e-06-0.4050image
ENSG00000188917.13,TRMT2BTHYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG5.5161e-06-0.4078image
chrX:101009521-101010435:-UCECGSVA_HALLMARK_MITOTIC_SPINDLEEER4.8459e-05-0.3046image
ENSG00000188917.13,TRMT2BUCECGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.4069e-04-0.2863image
chrX:101009521-101010435:-UCSGSVA_HALLMARK_DNA_REPAIREER2.8951e-020.3002image
ENSG00000188917.13,TRMT2BUCSGSVA_HALLMARK_DNA_REPAIREAG2.7217e-020.3034image
chrX:101009521-101010435:-UVMGSVA_HALLMARK_UV_RESPONSE_DNEER2.1633e-03-0.3511image
ENSG00000188917.13,TRMT2BUVMGSVA_HALLMARK_UV_RESPONSE_DNEAG2.1374e-03-0.3515image


Top

7. Enriched editing regions and drugs for TRMT2B


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000188917.13,TRMT2BACCABT.263EAG4.7305e-020.2268image
chrX:101009521-101010435:-ACCABT.263EER4.7305e-020.2268image
ENSG00000188917.13,TRMT2BBLCACI.1040EAG3.1170e-08-0.2723image
chrX:101009521-101010435:-BLCACI.1040EER2.3363e-08-0.2747image
ENSG00000188917.13,TRMT2BBRCAAxitinibEAG2.1764e-060.1441image
chrX:101009521-101010435:-BRCAABT.263EER1.0217e-060.1492image
ENSG00000188917.13,TRMT2BCESCCI.1040EAG7.2537e-07-0.2801image
chrX:101009521-101010435:-CESCCI.1040EER7.2759e-07-0.2800image
chrX:101009521-101010435:-CHOLCMKEER3.7666e-020.3528image
ENSG00000188917.13,TRMT2BCHOLCMKEAG3.5757e-020.3561image
ENSG00000188917.13,TRMT2BCOADMG.132EAG1.9715e-030.1872image
chrX:101009521-101010435:-COADJNK.Inhibitor.VIIIEER1.7384e-050.2606image
ENSG00000188917.13,TRMT2BDLBCBryostatin.1EAG1.3472e-03-0.4496image
chrX:101009521-101010435:-DLBCBryostatin.1EER1.3308e-03-0.4500image
chrX:101009521-101010435:-ESCAABT.263EER2.7580e-020.1742image
ENSG00000188917.13,TRMT2BESCAABT.888EAG9.1684e-03-0.2048image
chrX:101009521-101010435:-GBMBosutinibEER2.4047e-050.3243image
ENSG00000188917.13,TRMT2BGBMBosutinibEAG2.9934e-050.3207image
ENSG00000188917.13,TRMT2BHNSCCGP.60474EAG3.1238e-06-0.2125image
chrX:101009521-101010435:-HNSCCGP.60474EER3.2019e-06-0.2123image
chrX:101009521-101010435:-KICHCMKEER4.2382e-05-0.4850image
ENSG00000188917.13,TRMT2BKICHCMKEAG4.1967e-05-0.4852image
ENSG00000188917.13,TRMT2BKIRCAZD8055EAG9.4324e-08-0.2686image
chrX:101009521-101010435:-KIRCGDC.0449EER2.2435e-09-0.3002image
chrX:101009521-101010435:-KIRPBryostatin.1EER6.9693e-04-0.2000image
ENSG00000188917.13,TRMT2BKIRPBryostatin.1EAG6.8178e-04-0.2004image
chrX:101009521-101010435:-LAMLBI.D1870EER1.3183e-020.2113image
ENSG00000188917.13,TRMT2BLAMLBI.D1870EAG3.6008e-030.2403image
chrX:101009521-101010435:-LGGCMKEER3.0972e-030.1327image
ENSG00000188917.13,TRMT2BLGGCMKEAG3.0332e-030.1330image
ENSG00000188917.13,TRMT2BLIHCFTI.277EAG2.4648e-050.2279image
chrX:101009521-101010435:-LIHCFTI.277EER2.4459e-050.2280image
chrX:101009521-101010435:-LUADGemcitabineEER1.3151e-06-0.2141image
ENSG00000188917.13,TRMT2BLUADGemcitabineEAG5.5741e-07-0.2212image
chrX:101009521-101010435:-LUSCAP.24534EER1.7684e-030.1409image
ENSG00000188917.13,TRMT2BLUSCAP.24534EAG1.7722e-030.1409image
chrX:101009521-101010435:-MESOCCT007093EER2.4999e-030.3335image
ENSG00000188917.13,TRMT2BMESOCCT007093EAG2.4999e-030.3335image
ENSG00000188917.13,TRMT2BOVBIBW2992EAG3.9255e-08-0.3162image
chrX:101009521-101010435:-OVBIBW2992EER1.0059e-08-0.3296image
ENSG00000188917.13,TRMT2BPAADDMOGEAG3.2178e-040.2734image
chrX:101009521-101010435:-PAADDMOGEER2.9494e-040.2751image
ENSG00000188917.13,TRMT2BPCPGCamptothecinEAG3.1785e-02-0.1597image
chrX:101009521-101010435:-PCPGCamptothecinEER3.4581e-02-0.1572image
chrX:101009521-101010435:-PRADEmbelinEER6.6653e-060.2007image
ENSG00000188917.13,TRMT2BPRADEmbelinEAG7.3604e-060.1998image
ENSG00000188917.13,TRMT2BREADAMG.706EAG2.8119e-040.3664image
chrX:101009521-101010435:-READAMG.706EER2.8119e-040.3664image
ENSG00000188917.13,TRMT2BSARCCMKEAG3.3257e-030.1904image
chrX:101009521-101010435:-SARCCMKEER3.3273e-030.1904image
ENSG00000188917.13,TRMT2BSKCMGNF.2EAG8.0950e-04-0.1562image
chrX:101009521-101010435:-SKCMGNF.2EER8.0029e-04-0.1563image
ENSG00000188917.13,TRMT2BSTADKU.55933EAG1.1563e-02-0.1319image
chrX:101009521-101010435:-STADKU.55933EER1.3146e-02-0.1295image
chrX:101030087-101031219:-STADDasatinibEER3.7432e-02-0.4101image
chrX:101025828-101028361:-STADCMKEER1.1470e-020.5173image
chrX:101009521-101010435:-TGCTFTI.277EER1.5618e-020.1991image
ENSG00000188917.13,TRMT2BTGCTFTI.277EAG1.5182e-020.1999image
chrX:101009521-101010435:-THCAAZD6244EER7.1201e-12-0.3002image
ENSG00000188917.13,TRMT2BTHCAAZD6244EAG7.8610e-12-0.2996image
chrX:101009521-101010435:-THYMBAY.61.3606EER1.4082e-040.3462image
ENSG00000188917.13,TRMT2BTHYMBAY.61.3606EAG1.0759e-040.3518image
chrX:101009521-101010435:-UCECBMS.536924EER1.2228e-03-0.2446image
ENSG00000188917.13,TRMT2BUCECFTI.277EAG1.3936e-030.2418image
chrX:101009521-101010435:-UCSAICAREER3.4898e-020.2904image
ENSG00000188917.13,TRMT2BUCSAICAREAG3.4413e-020.2912image
chrX:101009521-101010435:-UVMA.770041EER1.2012e-03-0.3694image
ENSG00000188917.13,TRMT2BUVMA.770041EAG1.2300e-03-0.3686image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType